As routine diligence, OptimizeRx monitors performance of all client programs with which we are engaged so we can study outcomes and better understand performance impact on our clients' ability to measure return on marketing investment (ROI). In this instance, the study focused on a Major Depressive Disorder (MDD) therapy where a predictive targeting marketing campaign delivered nearly three times as many patients than the more traditional trigger-based marketing campaign. Enhanced Audience Quality: DAAP ide ...

• 84% of Patients Arrive at Doctor Visits Underinformed • Underscores Growing Importance of HCP and DTC Alignment in Pharma Commercialization and Marketing Strategies • OPRX Closes First Combined HCP and DTC DAAP Marketing Program for Top 5 Pharma Client WALTHAM, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, announced ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (IRS Employer Identificatio ...

OptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Conference Call May 14, 2024 2:30 PM ET Company Participants William Febbo - CEO Edward Stelmakh - CFO Steve Silvestro - President Andrew D'Silva - SVP of Corporate Finance Conference Call Participants Ryan Daniels - William Blair Eric Martinuzzi - Lake Street David Grossman - Stifel Constantine Davides - Citizen JMP Stephanie Davis - Barclays William Wood - B. Riley Securities Operator Good afternoon, everyone, and thank you for joining OptimizeRx's Fir ...

Exhibit 99.1 OptimizeRx Reports First Quarter 2024 Financial Results - Q1 revenue of $19.7 million, increasing 51% year-over-year - Q1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62% - Won 9 DAAP deals during Q1 WALTHAM, Mass. – May 14, 2024 – OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three ...

Shares of OptimizeRx Corp. (OPRX) have gained 0.5% over the past four weeks to close the last trading session at $10.81, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.57 indicates a potential upside of 34.8%. The average comprises seven short-term price targets ranging from a low of $8 to a high of $20, with a standard deviation of $3.69. While the lowest estimate indicate ...

WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:  RBC Capital Markets Global Healthcare Conference, New York City, May 14 – 15, 2024B.Riley Securities 24th Annual Institutional Investor Conference, Beverly Hills, May ...

1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, is prov ...

FORM 10-K For the fiscal year ended December 31, 2023 For the transition period from _________ to ________ (Exact name of registrant as specified in its charter) 02453 (ZipCode) Title of each class Trading Symbol Name of each exchange on which registered Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by th ...

OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants William Febbo - CEO Edward Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Office Conference Call Participants Sean Dodge - RBC Capital Markets Stephanie Davis - Barclays William Wood - B. Riley Securities Operator Good morning, everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2023 Conference Call. With us today is the Chief Executive O ...